

Attorney Docket No.: DEX-0532  
Inventors: Macina et al.  
Serial No.: 10/523,834  
Filing Date: April 26, 2006  
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the claims:**

Claims 1-18 (canceled)

Claim 19 (currently amended): An isolated monoclonal antibody, or antigen-binding portion thereof, which competes for binding to the epitope bound by an antibody which specifically binds an antigenic region of SEQ ID NO: 265 wherein the antigenic region to which the antibody specifically binds is selected from the group consisting of:

- (a) amino acid residues 59-65 of SEQ ID NO: 265;
- (b) amino acid residues 71-83 of SEQ ID NO: 265;
- ~~(c) amino acid residues 90-97 of SEQ ID NO: 265;~~
- ~~(d)~~ (c) amino acid residues 130-141 of SEQ ID NO: 265;
- ~~(e)~~ (d) amino acid residues 169-177 of SEQ ID NO: 265;
- ~~(f)~~ (e) amino acid residues 186-193 of SEQ ID NO: 265;
- ~~(g)~~ (f) amino acid residues 195-202 of SEQ ID NO: 265;
- and
- ~~(h)~~ (g) amino acid residues 226-240 of SEQ ID NO: 265.

Claim 20 (canceled)

Claim 21 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is a humanized antibody.

Claim 22 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the

Attorney Docket No.: DEX-0532  
Inventors: Macina et al.  
Serial No.: 10/523,834  
Filing Date: April 26, 2006  
Page 4

antibody, or antigen-binding portion thereof, is a chimeric antibody.

Claim 23-24 (canceled)

Claim 25 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is labeled.

Claim 26 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is conjugated to a toxin.

Claim 27 (currently amended): An isolated monoclonal antibody, or antigen-binding portion thereof, which specifically binds an antigenic region of SEQ ID NO: 265 wherein the antigenic region to which the antibody specifically binds is selected from the group consisting of:

- (a) amino acid residues 59-65 of SEQ ID NO: 265;
  - (b) amino acid residues 71-83 of SEQ ID NO: 265;
  - ~~(c) amino acid residues 90-97 of SEQ ID NO: 265;~~
  - ~~(d)~~ (c) amino acid residues 130-141 of SEQ ID NO: 265;
  - ~~(e)~~ (d) amino acid residues 169-177 of SEQ ID NO: 265;
  - ~~(f)~~ (e) amino acid residues 186-193 of SEQ ID NO: 265;
  - ~~(g)~~ (f) amino acid residues 195-202 of SEQ ID NO: 265;
- and
- ~~(h)~~ (g) amino acid residues 226-240 of SEQ ID NO: 265.

Claim 28 (canceled)

Attorney Docket No.:       **DEX-0532**  
Inventors:                   **Macina et al.**  
Serial No.:                  **10/523,834**  
Filing Date:                **April 26, 2006**  
Page 5

Claim 29 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is a humanized antibody.

Claim 30 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is a chimeric antibody.

Claim 31-32 (canceled)

Claim 33 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is labeled.

Claim 34 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is conjugated to a toxin.

Claims 35-42 (canceled)

Claim 43 (new): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is a human antibody.

Claim 44 (new): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is a human antibody.

Attorney Docket No.: DEX-0532  
Inventors: Macina et al.  
Serial No.: 10/523,834  
Filing Date: April 26, 2006  
Page 6

Claim 45 (new): An isolated monoclonal antibody, or antigen-binding portion thereof, which competes for binding to the epitope bound by an antibody which specifically binds an antigenic region of SEQ ID NO: 265 with an affinity of at least  $1 \times 10^{-6}$  molar (M), wherein the antigenic region to which the antibody specifically binds is selected from the group consisting of:

- (a) amino acid residues 59-65 of SEQ ID NO: 265;
- (b) amino acid residues 71-83 of SEQ ID NO: 265;
- (c) amino acid residues 90-97 of SEQ ID NO: 265;
- (d) amino acid residues 130-141 of SEQ ID NO: 265;
- (e) amino acid residues 169-177 of SEQ ID NO: 265;
- (f) amino acid residues 186-193 of SEQ ID NO: 265;
- (g) amino acid residues 195-202 of SEQ ID NO: 265; and
- (h) amino acid residues 226-240 of SEQ ID NO: 265.

Claim 46 (new): The antibody, or antigen-binding portion thereof, of Claim 45 wherein the antibody, or antigen-binding portion thereof, is a human antibody.

Claim 47 (new): The antibody, or antigen-binding portion thereof, of Claim 45 wherein the antibody, or antigen-binding portion thereof, is a humanized antibody.

Claim 48 (new): The antibody, or antigen-binding portion thereof, of Claim 45 wherein the antibody, or antigen-binding portion thereof, is a chimeric antibody.

Attorney Docket No.: **DEX-0532**  
Inventors: **Macina et al.**  
Serial No.: **10/523,834**  
Filing Date: **April 26, 2006**  
Page 7

Claim 49 (new): The antibody, or antigen-binding portion thereof, of Claim 45 wherein the antibody, or antigen-binding portion thereof, is labeled.

Claim 50 (new): The antibody, or antigen-binding portion thereof, of Claim 45 wherein the antibody, or antigen-binding portion thereof, is conjugated to a toxin.

Claim 51 (new): An isolated monoclonal antibody, or antigen-binding portion thereof, which specifically binds an antigenic region of SEQ ID NO: 265 with an affinity of at least  $1 \times 10^{-6}$  molar (M), wherein the antigenic region to which the antibody specifically binds is selected from the group consisting of:

- (a) amino acid residues 59-65 of SEQ ID NO: 265;
- (b) amino acid residues 71-83 of SEQ ID NO: 265;
- (c) amino acid residues 90-97 of SEQ ID NO: 265;
- (d) amino acid residues 130-141 of SEQ ID NO: 265;
- (e) amino acid residues 169-177 of SEQ ID NO: 265;
- (f) amino acid residues 186-193 of SEQ ID NO: 265;
- (g) amino acid residues 195-202 of SEQ ID NO: 265; and
- (h) amino acid residues 226-240 of SEQ ID NO: 265.

Claim 52 (new): The antibody, or antigen-binding portion thereof, of Claim 51 wherein the antibody, or antigen-binding portion thereof, is a human antibody.

Claim 53 (new): The antibody, or antigen-binding portion thereof, of Claim 51 wherein the antibody, or antigen-binding portion thereof, is a humanized antibody.

Attorney Docket No.:       **DEX-0532**  
Inventors:                   **Macina et al.**  
Serial No.:                  **10/523,834**  
Filing Date:                **April 26, 2006**  
Page 8

Claim 54 (new): The antibody, or antigen-binding portion thereof, of Claim 51 wherein the antibody, or antigen-binding portion thereof, is a chimeric antibody.

Claim 55 (new): The antibody, or antigen-binding portion thereof, of Claim 51 wherein the antibody, or antigen-binding portion thereof, is labeled.

Claim 56 (new): The antibody, or antigen-binding portion thereof, of Claim 51 wherein the antibody, or antigen-binding portion thereof, is conjugated to a toxin.